Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGF-R{alpha}-expressing Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumors (DSRCT)

Joseph Chao,G. T. Budd,Peiguo Chu,Paul Frankel,D. García,Maribel Junqueira,George Somlo,Judith K. Sato,Warren Chow

Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGF-R{alpha}-expressing Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumors (DSRCT)

2008

Joseph Chao
G. T. Budd
Peiguo Chu
Paul Frankel
D. García
Maribel Junqueira
George Somlo
Judith K. Sato
Warren Chow

10547 Background: The prognosis in metastatic or recurrent ESFT remains poor despite the success of multiagent chemotherapy for localized tumors. In a Children’s Oncology Group phase II study (Ped....

Keywords:

Clinical trial
Pathology
Sarcoma
Mesylate
Platelet-derived growth factor receptor
Imatinib
Cancer research
Medicine
round cell
imatinib mesylate
Alpha (ethology)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations